Company Overview

SANUWAVE Health, Inc. is a medical device company focused on the development and commercialization of noninvasive therapeutic products based on low-intensity shockwave technology. The company operates within the medical devices and regenerative medicine industries, with a primary emphasis on wound care and tissue regeneration. Its core technology platform is designed to stimulate healing in chronic, non-healing wounds by activating biological responses at the cellular level.

The company’s principal revenue drivers are its proprietary shockwave systems, most notably the dermaPACE® System, which is cleared by the U.S. Food and Drug Administration for the treatment of diabetic foot ulcers. SANUWAVE primarily serves hospitals, wound care centers, and clinicians treating chronic wounds. The company positions itself through a differentiated, noninvasive therapy that does not rely on drugs or biologics, offering a treatment option for patients with limited alternatives. SANUWAVE was founded in the early 2000s and evolved from broader orthopedic and musculoskeletal shockwave applications to a more focused strategy centered on chronic wound care.

Business Operations

SANUWAVE generates revenue primarily through the sale, lease, and per-procedure usage of its shockwave therapy devices, along with associated consumables and service agreements. Its main operating focus is the wound care segment, anchored by the dermaPACE® System, which uses acoustic pressure waves to stimulate blood vessel formation and tissue regeneration. The company also maintains research and development activities aimed at expanding clinical indications and improving device performance.

Operations are concentrated in the United States, with limited international activity conducted through distributors and strategic partners. SANUWAVE controls its core intellectual property related to shockwave delivery and treatment protocols. The company does not report significant manufacturing subsidiaries and relies on a combination of internal oversight and third-party manufacturing and logistics partners. Public disclosures indicate no material joint ventures; however, distribution relationships are used to support international market access.

Strategic Position & Investments

SANUWAVE’s strategic direction is centered on expanding adoption of its FDA-cleared wound care technology and pursuing reimbursement coverage to drive recurring revenue. Growth initiatives include increasing utilization in existing wound care centers, expanding sales coverage, and generating additional clinical evidence to support broader payer acceptance. The company has also indicated interest in expanding shockwave applications into other regenerative medicine indications, though the commercial timing of such initiatives remains uncertain based on public disclosures.

Historically, SANUWAVE has completed acquisitions of technology assets and intellectual property to consolidate its shockwave platform, including the integration of legacy shockwave systems into its current product lineup. The company does not report ownership of large operating subsidiaries, and information on material equity investments in other companies is limited. Data on emerging technology investments outside wound care is inconclusive based on available public sources.

Geographic Footprint

SANUWAVE Health, Inc. is headquartered in the United States, with its primary commercial and administrative operations based domestically. The majority of revenue-generating activity occurs within the U.S. healthcare system, particularly in outpatient wound care clinics and hospital-based programs.

Internationally, the company has a limited but developing presence in parts of Europe, Asia, and Latin America, primarily through independent distributors rather than direct operations. These markets represent potential long-term growth opportunities, but current international revenue contribution is not clearly delineated in public filings. The company does not disclose ownership of significant foreign facilities or manufacturing sites.

Leadership & Governance

SANUWAVE is led by an executive team with experience in medical devices, commercialization, and corporate restructuring. Governance is overseen by a board of directors responsible for strategic oversight, capital allocation, and regulatory compliance. Management’s stated philosophy emphasizes disciplined growth, clinical validation, and expanding market access for its core wound care technology.

Key executives include:

• Morgan Frank – Chief Executive Officer
• Andrew L. Carter – Chief Financial Officer
• Kevin Richardson – Chief Operating Officer
• Peter M. Saperia – Chairman of the Board

The leadership team’s strategic vision focuses on transforming SANUWAVE into a sustainable wound care solutions provider by leveraging FDA clearance, building clinical credibility, and pursuing reimbursement-driven adoption.